Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simvastatin Treatment in Patients with Liver Cirrhosis: a Phase II Randomized Placebo Controlled Trial Shows Reduction in IL-6 Levels.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

SLFN5 restrains type I interferon responses and promotes glioblastoma via its N-terminal Schlafen core domain.

Communications biology·2026
Same author

Multi-omics analysis reveals LARP1 as a key integrator of translation and metabolism in AML.

Oncogenesis·2026
Same author

Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.

Cancer metastasis reviews·2026
Same author

Development of a SIN1 Targeting Inhibitor as a Novel Therapeutic Approach for the Treatment of Malignancies.

Molecular cancer therapeutics·2025
Same author

Reprogramming SREBP1-dependent lipogenesis and inflammation in high-risk breast with licochalcone A: A novel path to cancer prevention.

International journal of cancer·2025

Related Experiment Video

Updated: Jan 13, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

623

Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia.

Jamie N Guillen Magaña1, Markella Zannikou1,2, Aneta Baran1,2,3

  • 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.

Cancer Research Communications
|October 28, 2025
PubMed
Summary

This study reveals the critical role of Schlafen 12 (SLFN12) in acute myeloid leukemia (AML) development. Velcrin compounds targeting SLFN12 show promise as a novel therapeutic strategy for AML.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.4K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.6K

Related Experiment Videos

Last Updated: Jan 13, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

623
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.4K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.6K

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Hematology

Background:

  • The Schlafen (SLFN) gene family, including SLFN12, comprises interferon-regulated genes implicated in cellular processes.
  • Leukemogenesis, particularly acute myeloid leukemia (AML), requires a deeper understanding of the molecular mechanisms driving cancer progression.
  • Identifying novel therapeutic targets is crucial for improving AML treatment outcomes.

Purpose of the Study:

  • To investigate the role of SLFN12 in the development of acute myeloid leukemia (AML).
  • To evaluate the therapeutic potential of velcrins, small molecules modulating SLFN12 activity, in AML.
  • To establish SLFN12 as a potential therapeutic target for AML.

Main Methods:

  • Examined the function of SLFN12 in leukemogenesis using AML cell models.
  • Assessed the effects of velcrin treatment on SLFN12 stability and complex formation with phosphodiesterase 3A/3B.
  • Evaluated the impact of velcrins on AML cell growth, apoptosis, and clonogenic capacity.
  • Tested velcrin efficacy in a mouse AML xenograft model.

Main Results:

  • Velcrin treatment stabilized SLFN12 and promoted its complex formation with phosphodiesterase 3A/3B in AML cells.
  • These molecular changes correlated with significant growth inhibition and apoptosis induction in leukemic cells.
  • Velcrins suppressed the clonogenic potential of primitive leukemic progenitors.
  • Treatment with velcrins significantly extended survival in a mouse model of AML.

Conclusions:

  • SLFN12 plays a significant role in the pathogenesis of acute myeloid leukemia.
  • Velcrins demonstrate potent anti-leukemic activity by targeting SLFN12.
  • These findings highlight SLFN12 as a promising therapeutic target for AML, with velcrins representing a potential novel treatment strategy.